Cargando…
Effectiveness of long‐term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease
BACKGROUND: Patients with symptomatic von Willebrand disease (VWD) should be offered long‐term prophylaxis (LTP) to prevent recurrent bleedings. Our objective was to evaluate the effectiveness and safety of Voncento®, a plasma‐derived FVIII/VWF concentrate (ratio 1:2.4), administrated in LTP. METHOD...
Autores principales: | Rugeri, Lucia, Harroche, Annie, Repessé, Yohan, Desprez, Dominique, Petesch, Brigitte Pan, Chamouni, Pierre, Biron, Christine, Frotscher, Birgit, Catovic, Hasan, Bracquart, Diane, Martin, Cédric, Trossaërt, Marc, Meunier, Sandrine, d'Oiron, Roseline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322399/ https://www.ncbi.nlm.nih.gov/pubmed/35438801 http://dx.doi.org/10.1111/ejh.13778 |
Ejemplares similares
-
Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders
por: Windyga, Jerzy, et al.
Publicado: (2022) -
A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis
por: Guillet, Benoit, et al.
Publicado: (2023) -
Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2022) -
The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022) -
BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)